Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Comparison of the combination of amlodipine with an angiotensin receptor blocker or an
angiotensin converting inhibitor, on central arterial blood pressure in patients with
hypertension and additional risk factors. This is a randomised, double-blind, double-dummy,
multicenter study. The duration of active treatment 24 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Daiichi Sankyo Europe, GmbH Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company